Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4551
CALL
Takeda Pharmaceutical
TAK
$55.8B
| $81.1K | ﹤0.01% |
+5,200
| New | +$74.3K |
|
|
ALMS
4552
PUT
Alumis Inc
ALMS
$3.23B
| $81K | ﹤0.01% |
+8,300
| New | +$57.9K |
|
4553
Urban One Class A
UONE
$23.5M
| $80.8K | ﹤0.01% |
7,841
+810
| +12% | +$9.96K |
|
4554
Arena Group
AREN
$76.2M
| $80.5K | ﹤0.01% |
20,135
+888
| +5% | +$3.98K |
|
4555
FT Vest US Equity Deep Buffer ETF December
DDEC
$435M
| $80.5K | ﹤0.01% |
1,785
-2,814
| -61% | -$125K |
|
4556
State Street SPDR S&P Semiconductor ETF
XSD
$2.85B
| $80.4K | ﹤0.01% |
250
| – | – |
|
4557
NextCure
NXTC
$30.8M
| $79.8K | ﹤0.01% |
5,626
| – | – |
|
|
TJAN
4558
Innovator Equity Defined Protection ETF - 2 Yr to January 2027
TJAN
$32M
| $79.8K | ﹤0.01% |
2,921
-79
| -3% | -$2.14K |
|
4559
FirstService
FSV
$6.3B
| $79.8K | ﹤0.01% |
513
-44,134
| -99% | -$7.18M |
|
4560
FT Vest US Equity Moderate Buffer ETF July
GJUL
$406M
| $79.4K | ﹤0.01% |
1,921
-3,046
| -61% | -$124K |
|
4561
Innovator US Equity Power Buffer ETF May
PMAY
$817M
| $79.3K | ﹤0.01% |
2,004
-1,796
| -47% | -$70.3K |
|
4562
Alvotech
ALVO
$1.29B
| $79.3K | ﹤0.01% |
15,459
-5,745
| -27% | -$36.3K |
|
|
OKUR
4563
OnKure Therapeutics
OKUR
$166M
| $79K | ﹤0.01% |
27,242
+26,621
| +4,287% | +$79.7K |
|
4564
OPAL Fuels
OPAL
$74.5M
| $78.6K | ﹤0.01% |
33,384
+3,156
| +10% | +$7.61K |
|
4565
Siebert Financial
SIEB
$68.8M
| $77.9K | ﹤0.01% |
22,183
+2,207
| +11% | +$7K |
|
|
SLSN
4566
Solesence Inc
SLSN
$72M
| $77.7K | ﹤0.01% |
48,744
-161
| -0.3% | -$436 |
|
4567
Alpha Teknova
TKNO
$378M
| $77.3K | ﹤0.01% |
20,342
+336
| +2% | +$1.64K |
|
|
LKFT
4568
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.88B
| $77K | ﹤0.01% |
2,355
-36,647
| -94% | -$1.18M |
|
4569
Pharvaris
PHVS
$2.41B
| $77K | ﹤0.01% |
+2,775
| New | +$66.8K |
|
4570
NLI Holdings
NL
$313M
| $76.9K | ﹤0.01% |
14,061
+1,282
| +10% | +$7.32K |
|
|
SBC
4571
SBC Medical Group
SBC
$328M
| $76.6K | ﹤0.01% |
17,779
+9,831
| +124% | +$37.5K |
|
|
SQMX
4572
FT Vest U.S. Equity Quarterly Max Buffer ETF
SQMX
$54.6M
| $76.5K | ﹤0.01% |
2,294
-3,496
| -60% | -$115K |
|
|
AFCG
4573
AFC Gamma
AFCG
$62.7M
| $76.4K | ﹤0.01% |
26,794
+1,038
| +4% | +$3.3K |
|
4574
Prairie Operating Co
PROP
$87M
| $76.1K | ﹤0.01% |
45,046
+13,953
| +45% | +$25.4K |
|
|
NTHI
4575
NeOnc Technologies
NTHI
$113M
| $75.7K | ﹤0.01% |
9,151
+8,982
| +5,315% | +$84.2K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.